Research Information System
19. Uluslararası Hipokrat Tıp ve Sağlık Bilimleri Kongresi, Ankara, Turkey, 10 - 11 October 2025, pp.230-231, (Full Text)
Objective: Transperineal prostate biopsy (TPBx) has emerged as an alternative to the transrectal approach due to its lower risk of infection and high diagnostic efficacy. This study aimed to present the outcomes of the first 35 TPBx cases performed at our center. Materials and Methods: Between June and September 2025, the data of 35 patients who underwent TPBx were retrospectively analyzed. Demographic characteristics, PSA levels, prostate volume, histopathological findings, complications, and VAS (Visual Analog Scale) pain scores were evaluated. Results: The mean age of the patients was 66.9 ± 6.5 years (range: 57–85). The mean PSA level was 21.4 ± 28.6 ng/mL (range: 4.65–146), and the mean prostate volume was 66.2 ± 32.4 mL (range: 36–175). Prostate cancer was diagnosed in 17 patients (48.5%). The Gleason score distribution was 3 + 3 (n = 7), 3 + 4 (n = 4), 4 + 3 (n = 2), 4 + 4 (n = 3), and 4 + 5 (n = 1). The mean number of positive cores among patients diagnosed with cancer was 4.29 ± 2.87 (range: 1–12). The mean intra-procedural VAS score was 2.82 ± 2.47. None of the patients developed fever or sepsis following the biopsy, and no hospitalization was required post-procedure. Conclusion: Transperineal prostate biopsy was successfully implemented for the first time in our center, demonstrating that it can be performed safely with acceptable cancer detection rates and a low risk of complications. These initial experiences from Kütahya indicate that the method can be safely adopted and expanded in routine clinical practice.